Companies › Fujian Akeylink Biotechnology
2 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 3; Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GST-HG141 HBV capsid assembly modulator (CAM) with distinct antiviral mechanism | – | Phase 3 | Chronic Hepatitis b; Chronic Hepatitis B | Dec 2026 |
| GST-HG131 Dihydroquinolizinone compound that reduces circulating HBsAg levels | – | Phase 2 | Chronic Hepatitis B | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06263959 | GST-HG131 | Phase 2 | Chronic Hepatitis B | Infectious disease | Apr 2025 |
| NCT07090759 | GST-HG141 | Phase 3 | Chronic Hepatitis b | Infectious disease | Dec 2026 |
| NCT07709520 | GST-HG141 | Phase 2 | Chronic Hepatitis B | Infectious disease | Dec 2026 |
| NCT07709520 | GST-HG131 | Phase 2 | Chronic Hepatitis B | Infectious disease | Dec 2026 |
No annotated target.
–
Ausper Biopharma Suzhou HepaThera Biotech TaiMed Biologics Labo'Life Laboratorio Farmaceutico SIT srl
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.